Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

Journal of Clinical Investigation

Volumn 101, Issue 12, 1998, Pages 2711-2719

  Hernández Perera, Octavio ^a   Pérez Sala, Dolores ^a   Navarro Antolín, Javier ^a   Sánchez Pascuala, Rafael ^a   Hernández, Gonzalo ^b   Díaz, Cristina ^b   Lamas, Santiago ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b Parke Davis SA   (Spain)

Author keywords

Endothelin; Endothelium; HMG CoA reductase; Nitric oxide; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CYCLIC GMP; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN PRECURSOR; SIMVASTATIN;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CATTLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MECHANISM; ENDOTHELIUM INJURY; HYPERLIPIDEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM;

EID: 0346736491     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1500     Document Type: Article

References (59)

1. Goldstein, J.L., and M.S. Brown. 1990. Regulation of the mevalonate pathway. Nature. 343:425-430.
2. Grünler, J., J. Ericsson, and G. Dallner. 1994. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim. Biophys. Acta. 1212:259-277.
3. Bocan, T.M.A., M.J. Mazur, S.B. Muller, E.Q. Brown, D.R. Sliskovic, P.M. O'Brien, M.W. Creswell, H. Lee, P.D. Uhlendorf, B.D. Roth, and R.S. Newton. 1994. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis. 111:127-142.
4. Witztum, J.L. 1996. Drugs used in the treatment of hyperlipoproteinemias. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, and A.G. Gilman, editors. McGraw-Hill, New York. 875-897.
5. Farmer, J.A., and A.M. Gotto, Jr. 1996. Current and future therapeutic approaches to hyperlipidemia. In Advances in Pharmacology. Vol. 35. J.T. August, M.W. Anders, F. Murad, and J.T. Coyle, editors. Academic Press, Inc., San Diego, CA. 79-114.
6. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:801-809.
7. Harrison, D.G., M.L. Armstrong, P.C. Freiman, and D.D. Heistad. 1987. Restoration or endothelium-dependent relaxation by dietary treatment of atherosclerosis. J. Clin. Invest. 80:1808-1811.
8. Cooke, J.P., A.H. Singer, P. Tsao, P. Zera, R.A. Rowan, and M.E. Billigham. 1992. Antiathcrogcnic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 90:1168-1172.
9. Creager, M.A., S.J. Gallagher, X.J. Girerd, S.M. Coleman, V.J. Dzau, and J.P. Cooke. 1992. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J. Clin. Invest. 90:1248-1253.
10. Kowala, M.C. 1997. The role of endothelin in the pathogenesis of atherosclerosis. In Advances in Pharmacology. Vol. 37. J.T. August, M.W. Anders, F. Murad, and J.T. Coyle, editors. Academic Press, Inc., San Diego, CA. 299-318.
11. Hirata, Y. 1996. Endothelin peptides. Curr. Opin. Nephrol. Hypertens. 5:12-15.
12. Webb, D. 1997. Physiological role of the endothelin system in human cardiovascular and renal hemodynamics. Curr. Opin. Nephrol. Hypertens. 6:69-73.
13. Moncada, S., and A. Higgs. 1993. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:2002-2012.
14. Rees, D.D., R.M.J. Palmer, and S. Moncada. 1989. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. USA. 86:3375-3378.
15. Lamas, S., and T. Michel. 1997. Molecular biological features of nitric oxide synthase isoforms. In Nitric Oxide and the Lung. Vol. 98. W.M. Zapol and K.D. Bloch, editors. Marcel Dekker, Inc., New York. 59-73.
16. Michel, T., and O. Feron. 1997. Nitric oxide synthases: which, where, how and why? J. Clin. Invest. 100:2146-2152.
17. Witztum, J.L., and D. Steinberg. 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1785-1792.
18. Chin, J.H., S. Azhar, and B.B. Hoffman. 1992. Inactivation of endothelial-derived relaxing factor by oxidized lipoproteins. J. Clin. Invest. 89:10-18.
19. Vaughan, C.J., M.B. Murphy, and B.M. Buckley. 1996. Statins do more than just lower cholesterol. Lancet. 348:1079-1082.
20. Marsden, P.A., T.A. Brock, and B.J. Ballermann. 1990. Glomerular endothelial cells respond to calcium-mobilizing agonists with release of EDRF. Am. J. Physiol. 258:F1295-F1303.
21. Pérez-Sala, D., D. Collado-Escobar, and F. Mollinedo. 1995. Intracellular alkalinization suppresses Lovastatin-induced apoptosis in HL-60 cells through the inactivation of pH-dependent endonuclease. J. Biol. Chem. 270: 6235-6242.
22. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
23. Marsden, P.A., D.M. Dorfman, T. Collins, B.M. Brenner, S.H. Orkin, and B.J. Ballermann. 1991. Regulated expression of endothelin 1 in glomerular capillary endothelial cells. Am. J. Physiol. 261:F117-F125.
24. Lamas, S., T. Michel, T. Collins, B.M. Brenner, and P.A. Marsden. 1992. Effects of Interferon-γ on nitric oxide synthase activity and endothelin-1 production by vascular endothelial cells. J. Clin. Invest. 90:879-887.
25. Lamas, S., P.A. Marsden, G.K. Li, P. Tempst, and T. Michel. 1992. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc. Natl. Acad. Sci. USA. 89:6348-6352.
26. Havel, R.J., H.A. Eder, and H.H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1345-1353.
27. Bochkov, V.N., V.A. Tkachuk, A.W.A. Hahn, J. Bernhardt, F.R. Buhler, and T.J. Resink. 1993. Concerted effects of lipoproteins and angiotensin II on signal transduction processes in vascular smooth muscle cells. Arterioscler. Thromb. 13:1261-1269.
28. Stanton, L.W., R.T. White, C.M. Bryant, A.A. Protter, and G. Endemann. 1992. A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein. J. Biol. Chem. 267:22446-22451.
29. Schuh, J., G.F. Fairclough, Jr., and R.H. Haschemeyer. 1978. Oxygen-mediated heterogeneity of apo-low-density lipoprotein. Proc. Natl. Acad. Sci. USA. 75:3173-3177.
30. Steinbrecher, U.P. 1987. Oxidation of human low density lipoprotein results in derivatizalion of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262:3603-3608.
31. Lamas, S., T. Michel, B. Brenner, and P. Marsden. 1991. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by TNF-α. Am. J. Physiol. 261:C634-C641.
32. Bredt, D.S., and S.H. Snyder. 1990. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. USA. 87:682-685.
33. Saura, M., S. López, M. Rodríguez Puyol, D. Rodríguez Puyol, and S. Lamas. 1995. Regulation of inducible nitric oxide synthase expression in rat mesangial cells and isolated glomeruli. Kidney Int. 47:500-509.
34. Marsden, P.A., M.S. Goligorsky, and B.M. Brenner. 1991. Endothelial cell biology in relation to current concepts of vessel wall structure and function. J. Am. Soc. Nephrol. 1:931-948.
35. Michel, T., G.K. Li, and L. Busconi. 1993. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 90:6252-6256.
36. Liao, J.K., W.S. Shin, W.Y. Lee, and S.L. Clark. 1995. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J. Biol. Chem. 270:319-324.
37. Nawrocki, J.W., S.R. Weiss, M.H. Davidson, D.L. Sprecher, S.L. Schwartz, P.-J. Lupien, P.H. Jones, H.E. Haber, and D.M. Black. 1995. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by Atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15:678-682.
38. McPherson, R., C. Tsoukas, M.G. Baines, A. Vost, M.R. Melino, R.V. Zupkis, and H.F. Pross. 1993. Effects of Lovastatin on natural killer cell function and other immunological parameters in man. J. Clin. Immunol. 13:439-444.
39. Grandaliano, G., P. Biswas, G.G. Choudhury, and H.E. Abboud. 1993. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int. 44:503-508.
40. Dunzendorfer, S., D. Rothbucher, P. Schratzberger, N. Reinisch, C.M. Kähler, and C.J. Wiedermann. 1997. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by Pravastatin. Circ. Res. 81:963-969.
41. Marsden, P.A., and B.M. Brenner. 1992. Transcriptional regulation of endothelin-1 by tumor necrosis factor-alpha. Am. J. Physiol. 262:C854-C861.
42. Cuthbert, J.A., and P.E. Lipsky. 1990. Inhibition by 6-fluoromevalonate demonstrates that mevalonate or one of the mevalonate phosphates is necessary for lymphocyte proliferation. J. Biol. Chem. 265:18568-38575.
43. Owens, D., P. Collins, A. Johnson, and G. Tomkin. 1990. Cellular cholesterol metabolism in mitogen-stimulated lymphocytes - requirement for de novo synthesis. Biochim. Biophys. Acta. 1051:138-143.
44. Cutts, J.L., and A.D. Bankhurst. 1990. Reversal of Lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin-2. J. Cell Physiol. 145: 244-252.
45. Zembowicz, A., J.-I. Tang, and K.K. Wu. 1995. Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine. J. Biol. Chem. 270:17006-17010.
46. Hirata, K., N. Miki, Y. Kuroda, T. Sakoda, S. Kawashima, and M. Yokoyama. 1995. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ. Res. 76:958-962.
47. Mathew, V., C.R. Cannan, V.M. Miller, D.A. Barber, D. Hasdai, R.S. Schwartz, D.R.J. Holmes, and A. Lerman. 1997. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation. 96:1930-1936.
48. Wilcox, J.N., R.R. Subramanian, C.L. Sundell, W.R. Tracey, J.S. Pollock, D.G. Harrison, and P.A. Marsden. 1997. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscl. Thromb. Vasc. Biol. 17:2479-2488.
49. Marsden, P.A., H.H.Q. Heng, S.W. Scherer, R.J. Siewart, A.V. Hall, X.-M. Shi, L.-C. Tsui, and K.T. Schappert. 1993. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J. Biol. Chem. 268:17478-17488.
50. Robinson, L.J., S. Weremowicz, C.C. Morton, and T. Michel. 1994. Isolation and chromosomal localization of the human endothelial nitric oxide synthase (NOS3) gene. Genomics. 19:350-357.
51. Laufs, U., V. La Fata, and J.K. Liao. 1997. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem. 272:31725-31729.
52. Flowers, M.A., Y. Wang, R.J. Stewart, B. Patel, and P.A. Marsden. 1995. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am. J. Physiol. 269 (Heart Circ. Physiol. 38): H1988-H1997.
53. Ziesche, R., V. Petkov, J. Williams, S.M. Zakeri, W. Mosgöller, M. Knöfler, and L.H. Block. 1996. Lipopolysaccharide and interleukin 1 augment the effects of hypoxia and inflammation in human pulmonary arterial tissue. Proc. Natl. Acad. Sci. USA. 93:12478-12483.
54. Kugiyama, K., S.A. Kerns, J.D. Morrisett, R. Roberts, and P.D. Henry. 1990. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344:160-162.
55. Boulanger, M.C., F.C. Tanner, M. Béa, A.W.A. Hahn, A. Werner, and T.F. Lüscher. 1992. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ. Res. 70:1191-1197.
56. Egashira, K., Y. Hirooka, H. Kai, M. Sugimachi, S. Suzuki, T. Inou, and A. Takeshita. 1994. Reduction in serum cholesterol with Pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:2519-2524.
57. Schmieder, R.E., and H.P. Schobel. 1995. Is endothelial dysfunction reversible? Am. J. Cardiol. 76:117A-121A.
58. Treasure, C.B., J.L. Klein, W.S. Weintraub, J.D. Talley, M.E. Stillabower, A.S. Kosinski, J. Zhang, S.J. Boccuzzi, J.C. Cedarholm, and R.W. Alexander. 1995. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332:481-487.
59. Eichstädt, H.W., H. Eskötter, I. Hoffman, H.W. Amthauer, and G. Weidinger. 1995. Improvement of myocardial perfusion by short-term Fluvastatin therapy in coronary artery disease. Am. J. Cardiol. 76:122A-125A.